← ANALYST RATINGS · TIPRANKS
Avalo Therapeutics (AVTX): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $49.00, the highest $60.00, the lowest $30.00. The average is +334.8% from the last price of $11.27.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $30.00 | Buy | +166.2% | Reiterated | 15.10.26on TipRanks 10:46 | +1.2%next day −5.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $14.50 → $11.50−20.7% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $14.50 → $11.50−20.7% | Sell | +2.0% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $14.00 → $11.50−17.9% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $13.50 → $11.50−14.8% | Sell | +2.0% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $15.00 → $11.50−23.3% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $14.00 → $11.00−21.4% | Sell | −2.4% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $60.00 | Buy | +432.4% | Reiterated | 01.10.26on TipRanks 07:08 | −2.7%next day −0.5% · 5 days −11.5% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $35.00 | Buy | +210.6% | Reiterated | 07.08.26on TipRanks 06:50 | −2.6%next day +7.9% · 5 days +6.5% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $50.00 → $48.00−4.0% | Buy | +325.9% | Reiterated | 06.08.26on TipRanks Aug 7 07:50 | −0.6%next day −2.6% · 5 days +2.8% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $58.00 | Buy | +414.6% | Reiterated | 06.08.26on TipRanks Aug 7 07:10 | −0.6%next day −2.6% · 5 days +2.8% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $38.00 | Buy | +237.2% | Initiated | 06.07.26on TipRanks 11:15 | +5.1%next day −3.1% · 5 days −5.0% | ↗ |
| Stacy Ku★★★★★★★★★★#2387 · hits 50% · avg +9.3% | TD Cowen | — | Buy | — | Reiterated | 11.06.26on TipRanks 05:55 | +2.7%next day +7.4% · 5 days +6.1% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $36.00 → $39.00+8.3% | Buy | +246.1% | Reiterated | 15.05.26on TipRanks May 17 22:08 | −5.5%next day −8.8% · 5 days −8.7% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $40.00 → $34.00−15.0% | Buy | +201.7% | Reiterated | 14.05.26on TipRanks 08:06 | −5.0%next day −5.5% · 5 days −11.9% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $62.00 → $55.00−11.3% | Buy | +388.0% | Reiterated | 14.05.26on TipRanks 06:00 | −5.0%next day −5.5% · 5 days −11.9% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $48.00 | Buy | +325.9% | Initiated | 08.04.26on TipRanks 16:45 | −2.0%next day −3.8% · 5 days −1.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Avalo Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $44.83 at a price of $15.33 (+192.5%); now: $46.20 at $11.27 (+309.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 21 | 14 | 12 | 4 | 4 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.59 (from $-0.98 to $-0.37). Last quarter: $-0.83.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Avalo Therapeutics
- CEO: Garry A. Neil
- Employees: 33
- 1500 Liberty Ridge Drive, Wayne, PA, 19087, US
- www.avalotx.com
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Data from the stock’s TipRanks forecast page, read 82 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗